Abstract
Trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab maytansine have improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have